This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Insider Trading Alert - DexCom And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 3, 2013, 116 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $30.21 to $14,999,997.60.

Highlighted Stocks Traded by Insiders:

DexCom (DXCM) - FREE Research Report

Gregg Terrance H who is Ceo at DexCom sold 9,000 shares at $27.99 on Oct. 3, 2013. Following this transaction, the Ceo owned 750,889 shares meaning that the stake was reduced by 1.18% with the 9,000 share transaction.

The shares most recently traded at $28.82, up $0.83, or 2.88% since the insider transaction. Historical insider transactions for DexCom go as follows:

  • 24-Week # shares sold: 18,633

The average volume for DexCom has been 530,100 shares per day over the past 30 days. DexCom has a market cap of $2.0 billion and is part of the health care sector and health services industry. Shares are up 106.11% year to date as of the close of trading on Thursday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently there are 8 analysts that rate DexCom a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings rates DexCom as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full DexCom Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community

Markets

DOW 18,072.27 -159.75 -0.88%
S&P 500 2,108.13 -17.93 -0.84%
NASDAQ 5,033.0330 -56.3290 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs